Author:
Shamash J,Dancey G,Barlow C,Wilson P,Ansell W,Oliver R T D
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer [comment]. J Urol 168: 2439–2443
2. Bhattacharyya M, Dancey G, Shamash J, Ong J, Ansell W, Wilson P, Oliver RTD (2003) Dexamethasone as an alternative to cortisone in combination with stilboestrol for hormone refractory prostate cancer. Br J Cancer 88(Suppl 1): S62 (abstr 147)
3. Bubley GJ, Carducci M, Dahut W (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17: 3461–3467
4. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Jackmaan S, Moul JW (2003) Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21: 4001–4008
5. Catane R, Kaufman JH, Madajewicz S (1978) Prednimustine therapy for advanced prostatic cancer. BJU Int 50: 29–32
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献